Morning Overview on MSN
Early trial: BIIB094 cuts Parkinson’s-linked LRRK2 protein up to 60%
For the roughly one million Americans living with Parkinson’s disease, every approved treatment does the same thing: manage symptoms. None slows the underlying brain degeneration. Results published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results